Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trilaciclib + GC in Metastatic TNBC
NCT02978716Phase 2Terminated
- Sponsor
- G1 Therapeutics, Inc.
- Start
- Feb 2017
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised, open-label trial of trilaciclib in myelosuppression (3 arms), sponsored by G1 Therapeutics, Inc. Primary endpoints: Duration of Severe (Grade 4) Neutropenia at Cycle 1 and Number of Participants With Severe (Grade 4) Neutropenia. Started Feb 2017; status: terminated.
02
Drugs
trilaciclib
03
Conditions
myelosuppression
Beyond the preview
Go deeper on NCT02978716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02978716.